# Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered

Source: https://onco.cc/technologies/rejuv-tx-long-term-follow-up-frameworks/  
OnCo record `rejuv-tx-long-term-follow-up-frameworks` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

There is an agreed international list of what should be checked in someone who has had a transplant, and how often, and an accreditation system that centres are inspected against. What there is much less of is a guarantee that any individual survivor is receiving the checks. Knowing the list exists lets a person ask for it.

## Summary

The screening recommendations. An international group of transplant experts convened in 2011 and published updated recommendations for screening and preventive practices for long-term survivors after transplant, updating a 2006 document, covering both paediatric and adult survivors of autologous and allogeneic transplant, written to be internationally applicable. This is the document behind most of the surveillance referred to elsewhere in this file: bone density, thyroid function, lipids and glucose, pulmonary function, ophthalmological assessment, iron status, gonadal function, cancer screening, vaccination and psychosocial assessment, each with a recommended population and interval. It is a consensus document drawing on the evidence available, not a set of randomised trial results, and it says so.

The accreditation standards. FACT, the Foundation for the Accreditation of Cellular Therapy, and JACIE, the Joint Accreditation Committee ISCT-Europe and EBMT, publish joint international standards. The FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing and Administration are in their ninth edition, and a separate set, the FACT-JACIE International Standards for Immune Effector Cells, in its third edition, covers programmes delivering CAR-T and other immune effector cells without hematopoietic transplantation. FACT describes these as covering hematopoietic progenitor cells from any tissue source, nucleated and mononuclear cells, immune effector cells and genetically modified cells. Accreditation is voluntary in principle; in practice, in Europe, JACIE accreditation is required for transplant activity in a number of countries and is widely treated as a condition of commissioning, and manufacturers of commercial CAR-T products require centre qualification before a product is released to them.

What accreditation does and does not guarantee is worth stating. It inspects the programme: quality management, staffing, training, chain of identity, data submission to a registry, and the existence of defined procedures including for long-term follow-up. It does not inspect whether a named survivor had a DXA scan last year.

The registries. The CIBMTR in the United States and the EBMT in Europe collect outcome data on transplants and, increasingly, on cellular therapies. Data submission is a standards requirement, and the registries are where the survival curves, the second cancer rates and the chronic GvHD incidence trends in this file come from. A survivor is, in effect, contributing to the evidence base that will describe the next cohort, which is an argument for staying in follow-up that is rarely put to people directly.

What a survivor is offered, in the US and the UK. In the United States, long-term follow-up is usually run by the transplant centre, often through a dedicated survivorship clinic at larger centres, with the recommendations above as the template; access depends on insurance and on distance, and transfer back to primary care is where surveillance is most often lost. In the United Kingdom, transplant activity is commissioned by NHS England from accredited centres and long-term follow-up is conducted by those centres and shared with general practice, with the British Society of Blood and Marrow Transplantation and Cellular Therapy publishing guidance for its members. An honest note on sourcing: the NHS England service specification page for haematopoietic stem cell transplantation did not return readable content to an automated request while this record was written, so the UK arrangements described here are taken from the BSBMTCT and from the published UK joint consensus statement on revaccination rather than from the commissioning document itself. A reader who needs the current UK specification should go to NHS England directly.

The gap this record exists to name. There is a published list of what should be done, an inspected standard for the programmes that should do it, and registries that record outcomes. There is no mechanism in either country that reliably tells an individual survivor, ten years out and living two hundred miles from the transplant centre, which tests they are due this year. The survivorship care plan, which OnCo covers on `survivorship-care-plan`, is the instrument designed to close that gap, and it works only if someone writes one.

## Fields

- Kind: Technology
- Status: standard-of-care
- Last checked: 2026-10-02
- Also known as: long-term follow-up after transplant; EBMT recommendations; CIBMTR screening recommendations; JACIE accreditation; FACT standards
- Tags: rejuvenation; survivorship; transplant; evidence:moderate; follow-up; standards
- Principle: Long-term safety in a small, highly specialised population cannot be assured by individual clinical judgement, because no single clinician sees enough survivors to recognise a pattern. It is assured instead by three linked mechanisms: a consensus list of what to look for, an inspected standard for the programmes that look, and registries that aggregate what is found so the list can be revised. The weak link is the handover from the specialist programme to generalist care.
- Since: 2012
- Strengths: An international, explicit screening list covering adults and children, autologous and allogeneic; FACT-JACIE accreditation inspects programmes against published standards, with separate standards for immune effector cells; Registry submission is a standards requirement, which is why the long-term data in this field exist at all; The documents are public, so a survivor can ask for a named test rather than a general review
- Limitations: Screening recommendations are consensus, not randomised evidence, and the intervals are pragmatic; Accreditation inspects programmes, not whether an individual received their checks; Follow-up is commonly lost at the handover to primary care; The NHS England service specification could not be read by automated request for this record, so the UK description rests on society guidance rather than the commissioning document

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation
- Majhail et al., Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation (Biol Blood Marrow Transplant 2012): https://doi.org/10.1016/j.bbmt.2011.12.519
- FACT standards: FACT-JACIE international standards for hematopoietic cellular therapy and for immune effector cells: https://www.factglobal.org/standards/
- EBMT: JACIE accreditation: https://www.ebmt.org/jacie-accreditation
- British Society of Blood and Marrow Transplantation and Cellular Therapy: guidelines: https://bsbmtct.org/bsbmtct-guidelines/
- Miller et al., Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients, on behalf of BSBMTCT, CCLG and the British Infection Association (J Infect 2023): https://doi.org/10.1016/j.jinf.2022.11.005
- Inamoto and Lee, Late effects of blood and marrow transplantation (Haematologica 2017): https://doi.org/10.3324/haematol.2016.150250

## Connected records

- technologies: [After a transplant or cell therapy: what to ask for](https://onco.cc/technologies/rejuv-tx-what-to-ask-for/), [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/), [Autologous stem cell transplant (high-dose therapy)](https://onco.cc/technologies/autologous-stem-cell-transplant/), [Bone, eyes, kidneys and lungs after transplant](https://onco.cc/technologies/rejuv-tx-bone-eyes-kidneys-lungs/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Iron overload after transplant](https://onco.cc/technologies/rejuv-tx-iron-overload/), [Late effects after a stem cell transplant](https://onco.cc/technologies/rejuv-tx-late-effects-overview/), [Long-term follow-up for gene-modified cell products: fifteen years, and why](https://onco.cc/technologies/rejuv-tx-gene-modified-follow-up/), [Revaccination after transplant: the schedules, and where the UK and the US differ](https://onco.cc/technologies/rejuv-tx-revaccination/), [Second cancers after allogeneic transplant](https://onco.cc/technologies/rejuv-tx-second-cancers/), [Survival after transplant, and why the curve never quite rejoins the population](https://onco.cc/technologies/rejuv-tx-survival-after-transplant/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [The lungs after transplant: bronchiolitis obliterans syndrome](https://onco.cc/technologies/gvhd-lung-bronchiolitis-obliterans/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- terms: [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Lost in Transition: the 2006 report that defined survivorship care, and the care plan it invented](https://onco.cc/terms/rejuv-history-lost-in-transition/), [Quality of life](https://onco.cc/terms/quality-of-life/)
- bottlenecks: [Nobody owns the follow-up once the oncology clinic lets go](https://onco.cc/bottlenecks/rejuv-agenda-nobody-owns-the-follow-up/), [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/)
- ideas: [Make the treatment exposure record machine-readable, so surveillance can be computed](https://onco.cc/ideas/idea-rejuv-exposure-record-a-machine-can-read/)
- trials: [AlloCare: a stepped-care late-effects service after allogeneic transplant](https://onco.cc/trials/rejuv-trial-allocare/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-tx-long-term-follow-up-frameworks.json